Samata Therapeutics

Redefining what’s possible in neurology

Contact us

Samata is developing transformative CNS medicines to overcome the limitations of current treatments.

Epliepsy

Pain

Neuropsychiatric Disorders

Samata is developing transformative CNS medicines to overcome the limitations of current treatments.

Epliepsy

Pain

Neuropsychiatric Disorders

Samata is developing transformative CNS medicines to overcome the limitations of current treatments.

Epliepsy

Pain

Neuropsychiatric Disorders

Epilepsy

~40% of Epilepsy Patients have Drug-Resistant Epilepsy

Epilepsy

~40% of Epilepsy Patients have Drug-Resistant Epilepsy

Epilepsy

~40% of Epilepsy Patients have Drug-Resistant Epilepsy

Pain

Pain is inadequately managed in >77% of chronic pain patients

Pain

Pain is inadequately managed in >77% of chronic pain patients

Pain

Pain is inadequately managed in >77% of chronic pain patients

Neuropsychiatric Disorders

>30% of depression patients are treatment-resistant

Neuropsychiatric Disorders

>30% of depression patients are treatment-resistant

Neuropsychiatric Disorders

>30% of depression patients are treatment-resistant

The Problem

Current therapeutics for Epilepsy, Pain, and Neuropsychiatric Disorders provide inadequate treatment alongside serious side-effects.

The Solution

We develop medicines with best-in-class pre-clinical efficacy by significantly reducing or eliminating adverse effects, expanding the therapeutic window for potent, clinically validated compounds.

Samata drugs target injured cells in vivo, avoiding healthy cells

GD2+ seizure

GD2+
no seizure

Left to right order: DAPI (Nuclei), Thy1-YFP (Neurons), Iba1 (Microglia), (Cy5) SMT-101, Composite (all overlaid). Should replace left-hand-side with SMT-101 + seizures, SMT-101 + no seizures. Mouse model of epilepsy. Sharma et. al. 2024 Bioengineering & Translational Medicine

Corporate Highlights

Highlight 1

Highlight 1

Highlight 1

Strong preclinical data package, with early proof-of-concept in therapeutic areas

Strong preclinical data package, with early proof-of-concept in therapeutic areas

Strong preclinical data package, with early proof-of-concept in therapeutic areas

Potential for POC in Human for Epilepsy in 2026-27

Potential for POC in Human for Epilepsy in 2026-27

Potential for POC in Human for Epilepsy in 2026-27

High capital efficiency; Only $15 M of spend needed to achieve Phase I success.

High capital efficiency; Only $15 M of spend needed to achieve Phase I success.

High capital efficiency; Only $15 M of spend needed to achieve Phase I success.

Accomplished team with track record of multiple approvals, clinical successes, platform expertise

Accomplished team with track record of multiple approvals, clinical successes, platform expertise

Accomplished team with track record of multiple approvals, clinical successes, platform expertise

Corporate Highlights

Epilepsy: SMT-101 is efficacious without side effects

Drug-resistant.

>40% of epilepsy patients are drug-resistant.

Side-effect profile.

Drug A is a powerful anti-epileptic drug clinically used for refractory Status Epilepticus but is not used as a general anti-epileptic due to serious side-effect profile.

Value proposition of SMT-101:

Reduces side effect profile (neurocognitive, sedation, etc.)

Reduces seizures compared to Drug A; both SMT-101 and Drug A have similar mechanisms.

Pain: SMT 201 durably treats pain while avoiding dependence

Dependence

Opioid pain medications drive severe dependence

Not sufficiently stop pain

Many non-opioid pain drugs do not sufficiently stop pain in many post-operative and severe acute or chronic pain contexts

Value proposition of SMT-201:

Effectively reduces/stops pain

Avoiding opioid use/dependence

Samata’s Development Focus

Preclinical Success with Epilepsy Identified as Lead Program

Our platform takes efficacious but toxic drugs and expands their therapeutic windows.

SMT 101: Indication: Epilepsy, Phase: Mid-Stage Preclinical

SMT 201: Indication: Pain, Phase: Early Stage Preclinical

SMT 301: Indications: Neuropsychiatric disorders, Phase: Lead Identification

SMT-101

SMT-201

SMT-301

Samata’s Development Focus

We're in mid-stage preclinical studies, focusing on epilepsy as a lead program.

Our platform takes efficacious but toxic drugs and expands their therapeutic windows.

SMT-101

Phase: Mid-Stage Preclinical

Indication: Epilepsy

SMT-101: Targeted non-dissociative, fast-acting, potent, and durable Anti-Glutaminergic agent

SMT-201: Targeted CB1R/CB2R engagement, durably reducing pain at the site of injury from systemic administration.

Phase: Early Stage Preclinical

Indication: Pain

SMT-201

SMT-301: Undisclosed

Phase: Lead Identification

Indication: Neuropsychiatric disorders

SMT-301

Samata’s Pipeline

Candidate

Indication

Chemistry

Lead Optimization

In-Vivo Efficacy

GLP Toxicity/Scale-Up

IND

SMT-101

Targeted non-dissociative, fast-acting, potent, and durable Anti-Glutaminergic agent

SMT-101

Targeted non-dissociative, fast-acting, potent, and durable Anti-Glutaminergic agent

SMT-101

Targeted non-dissociative, fast-acting, potent, and durable Anti-Glutaminergic agent

Epilepsy

Epilepsy

Epilepsy

SMT-102

Targeted CB1R/CB2R engagement, durably reducing pain at the site of injury from systemic administration.

SMT-102

Targeted CB1R/CB2R engagement, durably reducing pain at the site of injury from systemic administration.

SMT-102

Targeted CB1R/CB2R engagement, durably reducing pain at the site of injury from systemic administration.

Pain

Pain

Pain

SMT-103

Undisclosed Neuropsych disorders

Undisclosed Neuropsych disorders

Undisclosed Neuropsych disorders

Samata TherapeuticsSamata Therapeutics

Samata TherapeuticsSamata Therapeutics

Samata TherapeuticsSamata Therapeutics

Samata TherapeuticsSamata Therapeutics